Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Jul;76(1):1-6.
doi: 10.1111/j.1365-2125.2012.04476.x.

Future of the European Union regulatory network in the context of the uptake of new medicines

Joëlle M Hoebert  1 , Alar Irs, Aukje K Mantel-Teeuwisse, Hubert G M Leufkens
Affiliations

Future of the European Union regulatory network in the context of the uptake of new medicines

Joëlle M Hoebert et al. Br J Clin Pharmacol. 2013 Jul.
No abstract available

PubMed Disclaimer

Figures

Figure 1
Figure 1
Availability (in %) of all centrally approved medicines (2004) in 2005 and 2009. Countries are ordered (increasing order) on the x axis according to their number of rapporteur roles between 2004 and 2009. Data used for this study were obtained for all 25 EU member states (per 01/05/2004), except for the Mediterranean islands of Malta and Cyprus for which IMS had no data. Within countries, IMS uses the same method but the methodology used varies between countries and depends on the nature of the pharmaceutical supply systems. IMS collects data in over a hundred countries world-wide. Volume data were expressed in standard units (SU). This is a measure used by IMS derived from the number of doses. It is measured differently depending on the formulation of the medicine. Usually one SU equals one capsule, one tablet, one prefilled syringe, one dose of inhaled medicine or 5 ml of an oral suspension etc. If IMS does not collect data from all suppliers in a country they project the sample of a particular distribution channel to the national level. A medicine was defined as available if consumption in that year was ≥100 SU. The years 2005 and 2009 were chosen to see the differences between fast and slow uptakers. Countries are ordered along the x axis according to their contribution to the EU regulatory system with countries on the left hand side contributing to a lesser extent than countries on the right hand side. *For certain countries only retail data and no hospital data were available from IMS. These are marked with an asterisk. In these countries availability was determined for medicines used in the outpatient setting only (see Table 1). formula image, 2005; formula image, 2009
Figure 2
Figure 2
Average uptake in the year 2009 of all centrally approved medicines in 2004 and the number of rapporteur roles in 2004–2009 of each member state. *For certain countries only retail data and no hospital data were available from IMS. These are marked with an asterisk. Filled in markers (n = 8) refer to countries that joined the EU per 1 May 2004, the open markers (n = 15) refer to older EU member states
See this image and copyright information in PMC

References

    1. Healy EM, Kaitin KI. The European Agency for the evaluation of medicinal products' centralized procedure for product approval: current status. Drug Inf J. 1999;33:969–978.
    1. European Medicines Agency. What we do. 1995–2010. 2012. Available at http://www.ema.europa.eu/ema/index.jsp?curl=pages/about_us/general/gener... (last accessed 30 October 2012)
    1. European Medicines Agency. The European Medicines Agency Road Map to 2015. London: The Agency's Contribution to Science, Medicines, Health; 2010.
    1. Heads of Medicines Agencies. A strategy for the heads of medicines agencies, 2011–15. 2010.
    1. Heads of Medicines Agencies. Contact points for HMA and HMA-WGs: list of contacts. 2008. Available at http://www.hma.eu/fileadmin/dateien/HMA_joint/Contact_HMA_and_HMA_WGs.pdf (last accessed 24 March 2011)

MeSH terms

Substances